Investors Rushing To Take Advantage Of Global Cannabis Boom

 

Visionary Executive Behind Early Marijuana Success Stories Appears Poised to Do It Again with Scythian Biosciences Corp. (TSX.V: SCYB); (OTC: SCCYF)

One of the highest-upside investment opportunities available right now is in the booming legal marijuana market.

Experts are projecting that global spending on legal cannabis is projected to grow from its current level of just under $10 billion to a whopping $57 billion in the next ten years – a compound annual growth rate (CAGR) of roughly 20% per year.

 

“The world has never seen something that will have such consistent growth over such a long period of time as the cannabis industry,” said Troy Dayton, CEO of Arcview Market Research, a leading research firm.

Thanks to the growing legalization trend, a number of forward-thinking companies are now moving quickly to establish positions in newly-opened markets.

One such company is Scythian Biosciences Corp. (TSX.V SCYB); (OTC: SCCYF) – a trend-setting company that is making strides in research and development as well as licensing, cultivation and distribution.

Legalization Trend Sends Shares of Many Pot Stocks Soaring

 

Investors looking to play this once-in-a-lifetime legalization trend have seen shares of many marijuana companies soar.

In fact, since its debut in April 2017, the Horizons Marijuana Life Sciences Index ETF – an exchange traded fund that seeks to replicate the returns of the North American Medical Marijuana Index – has shot up 81.37%.

And shares of a number of individual cannabis stocks have soared over the past 12 months:

• Aurora Cannabis (TSE: ACB) – market cap $5.34 billion – has seen its shares rise by 381.82% over the past year…
• Canopy Growth Corp. (TSE: WEED) – market cap $6.69 billion – has shot up 228.9% during that time…
• OrganiGram Holdings Inc. (TSX.V: OGI) – market cap $593.9 million – has risen 115.32% over the past year…
• And Aphria Inc. (TSE: APH) – market cap $2.39 billion – has climbed 141.95% over the past 12 months.

But one company – a firm with an expanding global presence – offers investors what could be a smarter, more wide-ranging approach for tapping into the upside potential of the global cannabis boom.

And it’s a company being guided by some of the same executives that helped build Aphria Inc. (TSX: APH) – one of Canada’s first marijuana companies – into a successful firm with a $2.3 billion market cap.

 

Scythian Biosciences (TSX.V: SCYB); (OTC: SCCYF) Offers Research & Development PLUS Global Distribution Potential

 

That company is Scythian Biosciences Corp. (TSX.V: SCYB); (OTC: SCCYF).

Scythian Biosciences Corp. offers investors both a research and development cannabis play as well as exposure to the global marijuana markets as a distributor.

Just recently – in February 2018, Scythian Biosciences Corp. announced the closing of an offering that included an investment of more than $14 million into the company by Aphria Inc. (TSX: APH).

This investment makes Aphria Inc. a major stakeholder in Scythian Biosciences Corp – and Aphria has the opportunity to increase its position.

Aphria Inc., of course, is one of Canada’s leading producers, suppliers and sellers of medical cannabis and has established a reputation as one of the lowest-cost producers in the Canadian cannabis industry.

 

Visionary Executive is at it Again…

 

Scythian’s Board of Directors includes George Scorsis. Mr. Scorsis brings over 15 years of leadership experience, having led companies to rapid growth within highly regulated areas such as alcohol, energy drinks and, most recently, medical cannabis.

Mr. Scorsis was formerly with Mettrum Health Corp as President and helped build that company into a $430 million business prior to its acquisition by Canopy Growth Corp.

His Florida business – Liberty Health Sciences (CSE: LHS) – is poised to take advantage of significant near and mid-term growth opportunities in the rapidly-growing Florida market and has established a goal of becoming the lowest cost cannabis producer in the market.

Scythian Biosciences Now Poised to Enter Argentina Cannabis Market

On April 9, 2018 Scythian Biosciences Corp. (TSX.V: SCYB); (OTC: SCCYF) announced that ABP S.A. – the Argentina-based pharmaceutical import and distribution company that Scythian is in the process of acquiring – received its license to import CBD oil into Argentina.

Previously – in March 2018 – Scythian announced that it had entered into a letter of intent to purchase MMJ International Investments Inc., a company pursuing medical cannabis opportunities in South America. MMJ is the owner of ABP S.A.

 

With the potential acquisition of one of Argentina’s leading importers and distributors of pharmaceuticals – and with ABP S.A.’s receipt of its license to import CBD oil into Argentina – Scythian is taking a bold step into the Argentinian medical cannabis market.

If this deal is completed, it will give the company access to Argentina’s network of hospitals, doctors, retail pharmacies, private health providers and public health system and will advance the Company’s objective to provide patients with access to safe, pharmaceutical-grade medical cannabis.

 

Scythian Biosciences (TSX.V: SCYB); (OTC: SCCYF)
Has Also Entered the Jamaican Market

 

Soon after announcing its proposed entry into the Argentinian medical cannabis market, Scythian Biosciences Corp. (TSX.V: SCYB); (OTC: SCCYF) announced the next step in its plan to expand its reach globally.

On March 21, 2018 the company announced that the Jamaica Cannabis Licensing Authority has granted Marigold Jamaica Products Ltd., a company that Scythian is proposing to acquire a 49% stake in, five conditional licenses to research, cultivate, process and market medical cannabis, as well as provide therapeutic or spa services utilizing cannabis products.

 

The awarding of five licenses is the most ever granted to one company by the Jamaican Cannabis Licensing Authority and these licenses include:

• A Tier 3 conditional license to cultivate over five acres (20,235 square meters) of land with cannabis for medical, scientific and therapeutic purposes. Scythian is the first company to be granted this license for over five acres of cannabis cultivation.
• A Tier 2 conditional license to process cannabis for medical, scientific and therapeutic purposes, including the manufacturing of cannabis-based products, in a space of over 200 square meters.
• A herb house retail license to sell cannabis products for medical, scientific and therapeutic purposes, with a space for immediate consumption by consumers.
• A therapeutic retail license to provide therapeutic or spa services utilizing cannabis products.
• A research license to undertake all activities involved in the assessment, study, research, development and testing of products derived from all or any part of the cannabis plant.

Scythian Biosciences Announces its Intent to Enter the Colombian Cannabis Market

In April 2018, Scythian Biosciences Corp. (TSX.V: SCYB); (OTC: SCCYF) announced it had signed a binding letter of intent to acquire MMJ Colombia Partners Inc. This acquisition will result in 100% ownership of MMJ Colombia for Scythian and would provide entry into the Colombian market for Scythian.

The acquisition is conditional upon the completion of MMJ Colombia’s acquisition of ColCanna SAS and ColCanna’s receipt of the final Colombian licenses for the cultivation, production, research and export of medical cannabis CBD and THC extracts.

 

ColCanna is the first medical cannabis producer in the Colombian coffee zone to receive pending licenses to cultivate, produce, research, and export medical cannabis CBD and THC extracts.

It is a government-backed operation with 35 acres of available land in Chinchina, Caldas, Colombia, all of which is expected to be developed and used for the cultivation of cannabis. Located in a temperate climate that supports four harvests a year, the first of which is expected in late 2018, this area is ideal for year-round cultivation without the need for artificial climate control.

Currently, ColCanna is in the process of constructing over 500,000 square feet of total greenhouse production space and is planning to build its laboratory for the fabrication of cannabis extracts in a warehouse located in Pereira. Following construction, ColCanna anticipates that these facilities will be capable of producing over 2,600,000 ml of medicinal oil per year.

 

 

With its entry into Argentina, Jamaica and Colombia, Scythian Biosciences Corp. (TSX.V: SCYB); (OTC: SCCYF) has signaled its intent to become a significant player in the global cannabis distribution industry.

This entry into the global distribution market provides an outstanding complement to the company’s existing cannabinoid-based drug development program.

Scythian Biosciences Corp. Looks to Treat Traumatic Brain Injury with Cannabinoids

Scythian Biosciences Corp. (TSX.V: SCYB); (OTC: SCCYF) is in the process of developing a proprietary cannabinoid-based combination drug therapy for the treatment of concussions and traumatic brain injury.

In fact, Scythian’s first patent application covers a two-drug combination therapy for concussive treatment.

This therapy involves the combined use of an NMDA antagonist plus a CB2 agonist, either cannabinoid or non-cannabinoid. NMDA antagonists inhibit white blood cell activity within injured brain tissue, stopping cytokine release and further brain damage. CB2 agonists modulate the inflammatory response itself, easing the initial swelling and the resulting pressure of injured brain tissue against the skull.

 

Simply put, the company believes that through its unique technology, brain damage caused by concussions can be greatly mitigated by easing the aftereffects of the brain’s contact with the skull.

Most of the damage occurs during the inflammatory and immune responses which are triggered immediately following a brain injury.

It is precisely these processes that Scythian’s patent-pending technology aims to control, thereby helping the body repair brain tissue without the associated swelling and white blood cell infiltration.

Scythian’s second patent filing covers methods and compositions for treating gastrointestinal inflammation. This includes the use of the cannabinoid CBD, the same CB-2 agonist covered in our concussion treatment combination, together with an NMDA receptor or FAAH inhibitor to control intestinal inflammation.

 

Scythian Has Partnered with the University of Miami to Conduct Clinical Trials

 

Scythian has recently formed a collaboration with the University of Miami and its world-renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen.

The University of Miami believes that Scythian’s scientific approach shows significant promise and differs from previous approaches to treat this growing problem.

The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian’s clinical studies to be undertaken at their world-class facilities.

Nationally recognized behavioral neuroscientist Gillian Hotz is leading the University of Miami study. An expert in neurotrauma, concussion management and neurorehabilitation, Hotz has been the co-director of the Miller School’s Concussion Program since 1995.

In addition to the University of Miami partnership, Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.

 

Why Investors Should Consider Adding Shares of Scythian Biosciences Corp. (TSX.V: SCYB); (OTC: SCCYF)

 

Investors looking to take advantage of the booming global market for legal marijuana have already seen significant growth over the past 12 to 18 months.

The months ahead are projected for even stronger growth in the overall market as legalization becomes more widespread.

Scythian Biosciences Corp. (TSX.V: SCYB); (OTC: SCCYF) is positioning itself to take advantage of this global growth by pursuing opportunities in new markets, such as Argentina, Jamaica and Colombia to date.

This move to become a leading global distributor of medical marijuana is perfectly complemented by the company’s research and development efforts, as Scythian – in partnership with the University of Miami – pushes ahead with clinical trials of its cannabinoid-based combination drug therapy for the treatment of concussions and traumatic brain injury.

 

And just recently – on February 22, 2018 – Scythian Biosciences rang the closing bell at the Nasdaq Stock Market to mark the company’s admission into the Nasdaq International Designation program under the symbol “OTC – Nasdaq Intl: SCCYF”.

This Nasdaq International Designation will help increase the visibility of Scythian to the U.S. investment community and U.S. market makers.

Investors looking for smart exposure to the global legal marijuana industry should begin their due diligence right away and consider adding shares of Scythian Biosciences Corp. (TSX.V: SCYB); (OTC: SCCYF) to their portfolio.

 

Please read our disclaimer notice here: Disclaimer Notice

 

 

 

 

 

 

High Hampton Holdings (CSE: HC ; OTC: HHPHF) Offers Investors Smart, Diversified Exposure to North America’s Fastest-Growing Marijuana Market

The market for legal marijuana in California is already massive – and it’s projected to continue growing at an impressive rate.With more than 40 million residents, California represents the sixth-largest economy in the world…and the largest medical cannabis market in North America.

Recreational cannabis sales began in California on January 1, 2018 – and experts project that this market will generate billions in revenue over the next 12 months.

 

In fact, Arcview Market Research – a leading cannabis research firm – has projected California’s legal cannabis sales will grow at a compound annual growth rate (CAGR) of 23.1%, reaching an estimated $6.5 billion by 2020.

 

That company is High Hampton Holdings Corp. (CSE: HC ; OTC: HHPHF) – a unique “first-mover” seeking to consolidate California’s booming cannabis industry.

 

High Hampton Holdings Corp. (CSE: HC ; OTC: HHPHF) Offers a Multi-Faceted Growth Strategy

Many investors looking to profit from the early stages of marijuana in California are looking to companies focused exclusively on cannabis production. High Hampton Holdings Corp. (CSE: HC ; OTC: HHPHF), however, offers investors a multi-faceted growth strategy and engages in finance, real estate, licensing, distribution, branding and operations within the legal cannabis industry.

The recent legalization which took effect in California comes with unique restrictions and regulations that many companies will have difficulty navigating. Beginning January 1, 2018, all cultivation of marijuana in California now requires municipal AND state permits in order to legally operate.

The experienced leadership team at High Hampton Holdings Corp. (CSE: HC ; OTC: HHPHF) – including experts with both cannabis and finance backgrounds – anticipated these early “growing pains” and positioned the company as a resource for smaller companies in need of assistance.

Companies looking to grow and produce marijuana in California will need to meet high standards – and potentially relocate to facilities that are properly zoned within the state – in order to receive approval to begin production.

Zoned, Permitted Cultivation Areas Are Scarce …and In High Demand.

These zoned, permitted cultivation areas are, obviously, in high demand – and extremely scarce – throughout the state of California.

Many companies are now struggling to raise enough capital to not only begin production but purchase or lease land within a licensed cultivation zone.

This is where High Hampton Holdings Corp. (CSE: HC ; OTC: HHPHF) comes into play.

High Hampton’s subsidiaries intend to actively purchase land and buildings located in appropriate zones to engage in both royalty and leasehold agreements with tenants.

Compelling operating businesses offering ancillary products and services in the cannabis space are starved for growth capital and strategic partnerships.

High Hampton Holdings Corp. (CSE: HC ; OTC: HHPHF) will look to capitalize on these cash flowing operations by leveraging the company’s assets and management expertise to deliver value to shareholders.

The company will provide professional management and advisory services to up-and-coming cannabis companies through its capital markets team, compliance team, licensing team and brands & products supply chain.

 

High Hampton’s Coachella Property Presents Growth Opportunity

One of High Hampton Holdings Corp’s primary revenue streams will involve leasing cultivation facilities to prospective cannabis producers looking to comply with California’s new regulations.

High Hampton Holdings Corp. is looking to acquire real estate in cannabis-friendly regions of California so it can then leverage its experienced management team with its properties to create a vertically integrated supply chain.

To that end, in 2017 the company acquired 100% interest in a 10.8-acre property in the Coachella region of California and is pursuing Conditional Use Permits for cultivation and manufacturing.

 

Located 28 miles east of Palm Springs, the City of Coachella enjoys progressive leadership, as the city has passed an ordinance allowing cultivation, processing, distribution and testing.

The City of Coachella has already granted Conditional Use Permits (CUPs) to several other companies in the region that hold over 300,000 square feet of land and the region is known for having a highly trained agricultural workforce seeking a bright future in the cannabis industry.

This has made Coachella a much sought-after destination for cannabis cultivation operations…and High Hampton Holdings Corp. (CSE: HC ; OTC: HHPHF) has the advantage of already being on the ground within the city.

Once the company receives its Conditional Use Permit for its Coachella property, it will begin construction of phase one of the buildout of its 192,000 square foot cGMP greenhouse facility and 52,000 square foot admin/extraction/production and retail facility.

 

In addition – staying true to the company’s mission – High Hampton Holdings Corp. (CSE: HC ; OTC: HHPHF) continues to look into future acquisitions that will help the company consolidate California and bring value to its shareholders.

More than 30 Years of Combined Cannabis Experience Helps
Guide High Hampton Holdings Corp. (CSE: HC ; OTC: HHPHF)

When it comes to evaluating the prospects for any company in the rapidly-growing legal marijuana industry, it’s critically important that the company have a leadership team in place with experience in the sector.

High Hampton Holdings Corp. (CSE: HC ; OTC: HHPHF) is led by a proven management team with more than 30 years of combined cannabis experience. This diverse leadership group includes strong cannabis, political, legal and capital markets backgrounds…giving the company strong guidance in this early-stage growth market:

The Next 12 Months Could Bring Strong Activity for High Hampton Holdings Corp. (CSE: HC ; OTC: HHPHF)

 

Investors looking for opportunities to profit from the rapidly-growing legal cannabis market in California have a number of options to consider – including many prospective production companies.

But High Hampton Holdings Corp. (CSE: HC ; OTC: HHPHF) offers investors the advantage of an experienced management team plus a unique, diversified business model that could provide smarter exposure to this fast-moving market.

The next 12 months – which could feature the awarding of a Conditional Use Permit (CUP) and the beginning of construction on the Coachella property as well as additional potential acquisitions – could see a flurry of activity for High Hampton Holdings Corp. (CSE: HC ; OTC: HHPHF).

Investors looking to take advantage of California’s legal marijuana “boom” would be wise to begin their due diligence right away.

 

Please read our disclaimer notice here: Disclaimer Notice

 

 

 

Canadian Company Eviana Health Corp. (CSE: EHC) (OTC: EVNNF) Enters $10 Million Agreement With Organigram

 

TORONTO, ON, June 4, 2018 /CNW/ – Organigram Holdings Inc. (“Organigram”) (TSX VENTURE: OGI) (OTCQB: OGRMF) and Eviana Health Corporation (“Eviana”) (CSE: EHC) (OTC: EVNNF) (collectively the “Companies”) are pleased to jointly announce that the Companies have entered into a non-binding term sheet (the “Term Sheet”) whereby Organigram will make a significant equity investment into Eviana.

Eviana Health Corporation is a Canadian Securities Exchange listed company that was established with the aim of delivering customized consumer healthcare products using natural hemp strains of cannabis sativa for cannabinoid-based topical creams and products and cosmeceutical and nutraceutical merchandise.

Under the terms of the equity investment, which the Companies anticipate completing on or around July 13, 2018 (“closing date”), Organigram will invest $10,000,000 in cash into Eviana.

Additionally, the Term Sheet contemplates Organigram entering into an offtake agreement with Eviana for up to 50% of the cannabidiol (“CBD”) production of Eviana for a period of five years, subject to adjustment based on Organigram’s equity interest in Eviana.

“This agreement is a key facet of our ongoing international expansion efforts,” explains Greg Engel, CEO, Organigram. “Our investment and concurrent offtake agreement with Eviana will provide Organigram with a source of low-cost, high-quality CBD for the burgeoning medical market within Europe. The proven cultivation and processing costing model that Eviana has developed will allow us to bring a range of innovative products to the global CBD marketplace.”

The potential investment supports Organigram’s aggressive growth strategy and helps ensure that Organigram is well prepared to meet the international demand for CBD oil.

The agreement with Eviana will provide Organigram with a source of low-cost, high-quality CBD for the burgeoning medical market within Europe.

“We are very excited to have Organigram on board with us. Its support as both a financial and strategic partner will be a major benefit to the stakeholders of Eviana as we move forward in executing our vision to become the preeminent hemp-based CBD supplier in Europe” said Avram Adizes, CEO of Eviana.

Equity Investment

Under the terms of the equity investment, which the Companies anticipate completing on or around July 13, 2018 (“Closing Date”), Organigram will invest $10,000,000 in cash into Eviana for 8,695,652 common shares of Eviana (CSE:EHC) and common share purchase warrants (the “Warrants”) as follows: (i) 2,373,319 Warrants exercisable at $1.50 for 18 months; (ii) 3,337,480 Warrants exercisable at $1.75 for 24 months; and (iii) 3,087,487 Warrants exercisable at $2.00 for 36 months, all subject to certain acceleration provisions. The number of Warrants are subject to a proportional adjustment to result in Organigram holding a 40% interest in Eviana on a fully diluted basis immediately following the closing of the transaction.

Post-closing, it is currently expected that Organigram will own approximately 26% of Eviana’s outstanding shares on a non-diluted basis, and 40% on a fully diluted basis.

Offtake Agreement for CBD Oil and Equivalents

In addition to the strategic investment by Organigram, the Companies have negotiated the preliminary terms of an offtake agreement whereby Organigram (or an affiliate) shall have the right to purchase up to 50% of Eviana’s (or its wholly-owned subsidiary’s) annual CBD oil production (or comparable form including but not limited to crystals) at 95% of the agreed raw CBD oil (or equivalent) wholesale price for a period of five years. The option to purchase a percentage of Eviana’s annual CBD oil production is based on Organigram’s continued ownership in Eviana.

Closing of the transactions contemplated herein are subject to customary conditions for a transaction of this nature, including due diligence and regulatory approvals. The Term Sheet also provides for a 40-day exclusivity period binding on Eviana.

About Eviana Health Corporation

Eviana Health Corporation is a Canadian Securities Exchange listed company that was established with the aim of delivering customized consumer healthcare products using natural hemp strains of cannabis sativa for cannabinoid-based topical creams and products and cosmeceutical and nutraceutical merchandise. Eviana holds an option to acquire a 100% equity interest in Eviana Inc. (“EI”), an Ontario corporation, upon: (i) funding of at least $3M (which has been satisfied); and (ii) an additional payment of $50,000. Eviana intends to exercise the option on or before closing of the transaction with Organigram. Upon exercise of the option, Eviana will be obligated to make payments in the aggregate of $450,000 based on EI meeting certain EBITDA thresholds.

EI in turn holds 100% of Intiva Plus d.o.o and Eviana d.o.o which hold certain assets in Serbia relating to the cultivation of industrial hemp plant oil for the pharmaceutical, nutraceutical and cosmeceutical industry, including but not limited to:

• Over 50 metric tonnes of hemp biomass in inventory including harvests from the most recent 2017 harvest available for extraction;
• A 40,000 sq ft. processing facility in Mladenovo, Serbia (near Novi Sad);
• A 22,000 sq ft. pharma-grade leased facility in Belgrade which houses a soon-to-be commissioned Vitalis Supercritical CO2 Extraction System;
• Recently completed planting of 150 hectares for the 2018 hemp cultivation season.

About Organigram Holdings Inc.

Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest-quality, condition-specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and Organigram is regulated by the Access to Cannabis for Medical Purposes Regulations (“ACMPR”).

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information relating to each of Organigram and Eviana, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. Important factors – including the availability of funds, consummation of definitive documentation, the results of financing efforts, crop yields – that could cause actual results to differ materially from the expectations of Organigram or Eviana are disclosed in documents filed from time to time on SEDAR by each of Organigram and Eviana (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Each of Organigram and Eviana disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Please read our disclaimer notice here: Disclaimer Notice

 

 

 

EVIANA PAGE

 

 

Eviana Health (CSE:EHC) Poised to Reap Returns with Global Hemp CBD Demand Surges

Suffers of many medical afflictions will soon have more alternative nutraceutical choices to relieve their pain and symptoms. That’s good news for patients as well as for companies like Eviana Health Corp. (EHC.CN), which stands ready to take advantage of the growing worldwide market for hemp and hemp-based cannabidiol (“CBD”). The pullback is now complete and Canadian cannabis companies are projected to move much higher soon.

 

CBD Price Crosses $20,000 Per Kilogram in Europe

 

Eviana Health Corp. is currently a certified organic hemp grower. The company has 150 hectares (370 acres) of hemp now under cultivation which could translate into over $60,000,000 of pharma grade CBD. It also one of the largest hemp producers in Europe. This puts the company in a strong position to harvest potential gains as hemp realizes increasing market acceptance in the medicinal market as well as other uses. Eviana looks grossly undervalued here, considering the stock is now trading at just over a buck a share.

With its recent investment announcement from Canadian medical cannabis leader, Organigram Holdings Inc. (“Organigram”) (TSX VENTURE: OGI) (OTCQB: OGRMF) which highlighted Orgaignram’s potential investment in the Company for cash and stock, the future growth plans for this CBD provider are bright.  Under the terms of the equity investment, which the Companies anticipate completing on or around July 13, 2018 (“Closing Date”), Organigram will invest $10,000,000 in cash into Eviana (CSE:EHC) for 8,695,652 common shares of Eviana and common share purchase warrants.

 

The Medical Benefits of CBD Are Coming into Focus and EVIANA is Now Well Positioned 

 

Whether intended for recreational or medicinal use, cannabis and hemp produce two chemical compounds. One is cannabidiol (CBD). The other is tetrahydrocannabinol (THC). THC is what gets a user “high.” As such, it is often viewed in a bad light by law enforcement authorities and is illegal for any use in many U.S. states. CBD, on the other hand, offers the same pain regulation benefits as THC, but does not produce a psychoactive reaction (the high). This means it receives a better reception from lawmakers who may be sympathetic towards medicinal users but who do not want to encourage people getting high.

 

Cannabis and hemp are botanical cousins. But there are significant differences between the plants. While hemp also produces THC, it’s only in trace amounts compared cannabis. Both plants also produce CBD. However, It’s easier to grow hemp and to extract CBD from it than to do the same with cannabis. While medicinal cannabis has enjoyed tremendous growth, its THC content may provide an opening for hemp to overtake it in the coming years.

 

One of the Largest Growth Trajectories of any Sector

 

Industry watchers are currently forecasting global spending on legal cannabis market to reach $57 billion by 2027. Most of that – $47 billion – will be spent in North America. Medicinal users want pain relief and symptom stabilization. They are not interested in getting high. So CBD from hemp is just as effective for them as CBD from cannabis. And CBD from hemp, as it has a better perception in legal circles, may be easier to obtain, creating a largely untapped, but soon to be growing market.

Sales of hemp-produced CBD products have more than doubled since 2016, recently reaching the $200 million mark.

The market is expected to grow even faster in the coming years, topping $1.8 billion by just 2020. That’s more than a 700 percent increase in only two years.

 

Besides CBD for nutraceuticals, hemp also has other uses. These other uses include foodstuffs, textiles, personal care products and building materials. These other uses propelled hemp sales to $688 million in 2017. The overall hemp market has been growing at a strong 22 percent compound annual rate over the past five years. This number is expected to continue to go up as restrictions on hemp are eased.

Please read our disclaimer notice here: Disclaimer Notice

 

 

 

 

EVITRADE PAGE

 

Evitrade’s (CSE:EVA) Proposed “Seed-to-Sale” Blockchain Protocol to Revolutionize Hemp/CBD Industry

 

A rolling stone may gather no moss, according to an old adage, but it does have plenty of momentum. Canada’s EVITRADE Health Systems Corp. (CSE:EVA or in the States OTCQB:AXHLF) has momentum as well, and while the company is definitely not gathering any moss, it is collecting an impressive list of achievements centered around another plant.

Evitrade’s latest accomplishment promises to bring Blockchain technology and security to the international hemp market. Evitrade seeks to deliver a unique “seed-to-sale” protocol that will help the company cultivate its growing reputation as an industry leader. Should the protocol be successful, it will enable Evitrade (CSE:EVA) to ensure the integrity of global sales of hemp-based cannabidiol (CBD) to medicinal users. Patients use CBD from hemp and cannabis to relieve pain and stabilize symptoms.

 

CBD Price Crosses $20,000 Per Kilogram in Europe

 

Demand for hemp and hemp-derived CBD have soared. Sales of hemp-produced CBD products have more than doubled since 2016, recently reaching the $200 million mark. However, the market is expected to grow even faster in the coming years, topping $1.8 billion by just 2020. That’s more than a 700 percent increase in only two years.

 

The Medical Benefits of CBD are Coming into Focus and Evitrade is Well Positioned

 

Whether intended for recreational or medicinal use, cannabis and hemp produce two chemical compounds. One is cannabidiol (CBD). The other is tetrahydrocannabinol (THC). THC is what gets a user “high.” As such, it is often viewed in a bad light by law enforcement authorities and is illegal for any use in many U.S. states. CBD, on the other hand, offers the same pain regulation benefits as THC, but does not produce a psychoactive reaction (the high). This means it receives a better reception from lawmakers who may be sympathetic towards medicinal users but who do not want to encourage people getting high.

 

Cannabis and hemp are botanical cousins. But there are significant differences between the plants. While hemp also produces THC, it’s only in trace amounts compared cannabis. Both plants also produce CBD. However, It’s easier to grow hemp and to extract CBD from it than to do the same with cannabis. While medicinal cannabis has enjoyed tremendous growth, its THC content may provide an opening for hemp to overtake it in the coming years.

 

Tailor-Made CBD Nutraceuticals Just Around the Corner

 

Thanks to a recent acquisition, Evitrade is now developing technologies that can ensure needed consistency in plant-based medicines.  This means Evitrade will be able to produce hemp- and cannabis-based CBD nutraceuticals with such finely tuned active ingredients as to meet an individual patient’s exact needs. And, with the added consistency, a batch of such tailor-made CBD can be precisely recreated as needed. Such finely-tuned medicines could previously only be done via chemicals.

 

One of the Largest Growth Trajectories of any Sector

 

Industry watchers are currently forecasting global spending on legal cannabis market to reach $57 billion by 2027. Most of that – $47 billion – will be spent in North America. Medicinal users want pain relief and symptom stabilization. They are not interested in getting high. So CBD from hemp is just as effective for them as CBD from cannabis. And CBD from hemp, as it has a better perception in legal circles, may be easier to obtain, creating a largely untapped, but soon to be growing market.

 

Besides CBD for nutraceuticals, hemp also has other uses. These other uses include foodstuffs, textiles, personal care products and building materials. These other uses propelled hemp sales to $688 million in 2017. The overall hemp market has been growing at a strong 22 percent compound annual rate over the past five years. This number is expected to continue to go up as restrictions on hemp are eased.

Please read our disclaimer notice here: Disclaimer Notice